The purpose of this review is to highlight recent research and insights into the relationship between fertility drug use and ovarian cancer risk.
INTRODUCTION
In 2013, there are expected to be approximately 22 240 incident cases of ovarian cancer and 14 030 deaths due to ovarian cancer in the United States [1] . Ovarian cancer is a complex, multifactorial disease that, unfortunately, is often detected at a late stage; the majority of ovarian cancer cases are diagnosed with regional or distant disease when 5-year survival rates are 72 and 27%, respectively [2] . There is a pressing need to identify women at an increased risk for ovarian cancer as well as to identify diseaserelated early symptoms, as this may result in the development of strategies that help prevent and/or lead to earlier detection of the disease. Fertility drug use has increased markedly in developed countries and is expected to increase further due to more and more women postponing attempts to become pregnant until after 35 years of age [3] . Use of ovulationinducing drugs has been hypothesized to increase the risk of several cancers, including ovarian cancer, and there has been concern about the long-term effects of fertility drugs ever since they were first prescribed. However, despite concerns about potential negative side effects and the growing number of women utilizing fertility drug treatments, the independent effects of fertility drug use on risk of ovarian cancer have remained poorly understood. This review highlights recent research and insights into the relationship between fertility drug use and ovarian cancer risk.
TWO THEORIES
Nulliparity, late onset of menopause and infertility are some of the factors known to be associated with an increased risk of ovarian cancer [4] [5] [6] [7] [8] [9] [10] [11] [12] , whereas oral contraceptive use and breast feeding have been reported associated with a decreased risk [12] [13] [14] [15] [16] [17] [18] . Two theories, the 'incessant ovulation' theory and the 'elevated gonadotropin levels' theory, have been proposed to explain the mechanisms by which these factors affect risk of ovarian cancer. According to the so-called 'incessant ovulation' theory, the repeated damage and subsequent repair cycles that occur during ovulation on the epithelial surface of the ovary contribute to DNA damage and so increase the risk of ovarian cancer [19] [20] [21] [22] . The consistent protective effect observed with factors that reduce the number of lifetime ovulations such as pregnancy and breastfeeding supports this theory. In addition, the fact that chickens, a species of incessant ovulators, are found to have an increased risk of ovarian cancer supports this theory as well [23] . The 'elevated gonadotropin levels' theory hypothesizes that exposure to high levels of circulating pituitary gonadotropins, which stimulates the ovarian surface epithelium and so increases the risk of malignant changes, plays an important role in the development of ovarian cancer [24, 25] . The decreased risk of ovarian cancer associated with each additional pregnancy and oral contraceptive use supports this theory. Infertility increases risk of ovarian cancer according to these theories because infertile women are less likely to reduce their lifetime number of ovulations by becoming pregnant and breastfeeding. In addition, they may also have shorter periods of oral contraceptive use with longer time attempting to become pregnant. It should be noted though that the link with ovarian cancer may also be (in part) due to pathologic conditions associated with infertility. That is, an anomaly of the ovaries may result in infertility as well as an increased risk of cancer. Importantly, the two theories also suggest that use of fertility drugs, which stimulate ovulation and create a condition of high gonadotropin levels, may increase the risk of ovarian cancer. Moreover, based on this, use of fertility drugs would in particular be a concern for infertile women who do not get pregnant despite using ovulation-inducing drugs.
FERTILITY DRUGS
Fertility drugs promote maturation of multiple follicles and, consequently, multiple ovulations by increasing gonadotropin levels. Commonly prescribed fertility drugs are clomiphene citrate, a selective oestrogen receptor modulator with chemical properties similar to tamoxifen that is often the first choice for treating infertility and has been around since the early 1960s, and gonadotropins such as human menopausal gonadotropin (hMG), folliclestimulating hormone (FSH), human chorionic gonadotropin (hCG) and gonadotropin releasing hormone (GnRH). These drugs can be used alone or in combination depending on the cause of infertility and the treatment protocol used. Fertility drugs are also an important part of the treatment when utilizing assisted reproductive techniques such as in-vitro fertilization (IVF). In particular, gonadotropins are often used in conjunction with IVF. IVF has been used to help women become pregnant since the late 1970s.
EARLIER STUDIES
In the 1990s, several epidemiological studies, including a meta-analysis of 12 case-control studies, reported an association between use of fertility drugs and the development of ovarian cancer [26] [27] [28] . These publications raised substantial concern regarding the safety of ovulation-inducing drugs and prompted multiple other investigations. Several subsequent case-control and cohort studies did not provide evidence of an increased risk of ovarian cancer with the use of fertility drugs [29] [30] [31] [32] [33] [34] . However, concern regarding potential side effects of fertility drugs remained after other studies reported that women who were treated with fertility drugs for more than 12 cycles had an increased risk of ovarian cancer [35, 36] . In addition, results from several of these earlier studies indicated that women who remained nulligravid after fertility treatment may be at an increased risk for ovarian cancer and also that fertility drugs may preferentially increase the risk of borderline ovarian tumours [26] [27] [28] 32, [37] [38] [39] [40] . Results from the few earlier studies that examined the relationship between IVF treatment and risk of ovarian cancer have been conflicting as well, with
KEY POINTS
Early studies suggested that use of fertility drugs increased the risk of developing ovarian cancer, which raised concern regarding the safety of the drugs.
Use of fertility drugs is highly correlated with many other factors that affect ovarian cancer risk, which complicates teasing out the contribution of fertility drug treatments.
Results from more recent studies have been primarily reassuring; most studies observed no association between fertility drug use and overall ovarian cancer risk.
Impact of fertility drug treatment on certain subgroups, including long-term fertility drug users, women who remain nulligravid and borderline ovarian tumours, is not yet clear.
Because many of the women treated with fertility drugs are only now beginning to reach the ovarian cancer age range, it may just be too early to determine whether fertility drug use increases ovarian cancer risk. some reporting no link between IVF treatment and ovarian cancer risk [41] [42] [43] [44] , although others found an increased risk of ovarian cancer in IVF users [45,46,47 & ]. In the largest study to date, involving 77 cases that developed in a Dutch cohort with a median follow-up of 15 years, a significantly increased risk was observed for both invasive and borderline ovarian cancer cases [47 & ].
RECENT STUDIES
Results from two recent case-control studies conducted in the United States provide further evidence that fertility drug use does not significantly contribute to risk of ovarian cancer among the majority of women when adjusting for known confounding ] used data from the Mayo Clinic Ovarian Cancer study. Strengths of both studies include a relatively large sample size and the availability of detailed reproductive and medical histories of study participants. Importantly, the ability to stratify and adjust for factors linked to ovarian cancer risk allowed the investigators to disentangle risk associated with these factors from risk associated with fertility drug use. Similar to previous reports, subgroup analyses in the HOPE study did find a statistically significant increased risk of ovarian cancer for use of fertility drugs among women who, despite seeking medical attention for infertility, remained nulligravid. Neither study observed a significant association between fertility drug use and risk of borderline ovarian tumours.
Several The investigators specifically discuss the potential of surveillance bias in their study and note that women treated with IVF were not diagnosed significantly sooner or at a younger age than women not treated with IVF. The same cohort was used to examine the effect of IVF treatment on risk of invasive ovarian cancer, reported in a separate publication [52 & ]. Thirty-eight women in the cohort were diagnosed with ovarian cancer. IVF treatment was not significantly associated with overall risk of invasive ovarian cancer. In analyses stratified by parity, there was some evidence of a more pronounced effect of IVF treatment in women who did not give birth. However, none of these associations was statistically significant either.
To derive a larger number of ovarian cancer cases, Siristatidis et al. [53] conducted a metaanalysis of nine cohort studies involving in total 109 969 women who received IVF treatment of whom 76 were diagnosed with invasive ovarian cancer. None of the recent studies discussed above were included, and all included studies were published earlier. All included studies reported comparisons with the general population in their original publication, but only four reported comparisons of IVF treated with non-IVF treated infertile women. Also, follow-up time in most of the studies was less than 10 years. Combined analysis with the general population as a reference group showed a statistically significant association between IVF treatment and risk of invasive ovarian cancer. However, no significant associations were observed when non-IVF treated infertile women were used as reference group.
COMPLICATIONS AND LIMITATIONS
Establishing the relationship between fertility drug use and ovarian cancer risk is complex due to the fact that infertility itself increases the risk of ovarian cancer [9] [10] [11] [12] . Moreover, use of fertility drugs correlates highly with many other factors that affect ovarian cancer risk such as cause of infertility, parity and use of oral contraceptives, which further complicates teasing out the contribution of fertility treatments.
Many of the studies that attempted to evaluate the link between fertility drug use and ovarian cancer have been hindered by methodological limitations, which may explain the conflicting results. The case-control studies often included only small numbers of study participants who had been exposed to fertility drugs and relied on participant reports of drug use, which can be imprecise and affected by case-control status. The cohort studies often had small numbers of ovarian cancer cases and short follow-up times. In addition, many studies lacked information on cause of infertility (or indication for fertility drug use), did not have appropriate comparison groups and or were unable to control for other important reproductive factors known to affect ovarian cancer risk (such as parity) due to either small numbers or absence of relevant data. More recent studies that have overcome some of these limitations reported no association between fertility drug use and overall ovarian cancer risk. However, questions regarding the effect on certain subgroups, including long-term fertility drug users, women who remain nulligravid after fertility treatment, women with BRCA1 or BRCA2 mutations and borderline ovarian tumours, still remain.
Regarding borderline ovarian tumours, results from both earlier and more recent studies suggest that fertility drugs may specifically increase the risk of borderline ovarian tumours. Borderline ovarian tumours are low-grade ovarian malignancies with an indolent disposition which, unlike invasive ovarian tumours, do not invade the underlying ovarian stroma [54] . They are more likely to be diagnosed in women of reproductive age than invasive ovarian tumours [55] , and have a better prognosis [56] . It has been speculated that the observed association with borderline ovarian tumours could be due to fertility drugs inducing growth in existing indolent tumours. Alternatively, the reported findings may not be causal but rather simply reflect more intensive medical surveillance among infertile women.
One of the largest problems currently might be that it may just be too early to establish whether there is an association between fertility drug use and ovarian cancer risk given that many of the exposed women are only now beginning to reach the ovarian cancer age range. Further long-term follow-up of women treated with fertility drugs is necessary. This will be especially important for the evaluation of newer fertility drugs such as gonadotropins and for the assessment of IVF treatment.
CONCLUSION
Although the historic literature is inconsistent, most recent studies observed no association between fertility drug use and risk of ovarian cancer and have been primarily reassuring. However, some have suggested possible risk increases among women who despite fertility drug use remain nulligravid, and those developing borderline tumours. In addition, information on the effects of long-term fertility drug use and the effects of fertility treatment on women who have a BRCA1 or BRCA2 gene mutation is currently scarce. Given the large number of women utilizing fertility treatment, it is essential to continue to monitor and further clarify the effects of fertility drug use on ovarian cancer risk so that healthcare providers and women seeking treatment can make better informed decisions. Large well designed studies that have sufficient follow-up time and consider cause of infertility, treatment details (such as number of cycles, dose and type(s) of fertility drug used) and other potential confounding factors (such as parity, oral contraceptive use and family history) are needed to evaluate the effects of fertility treatment within subgroups defined by patient and tumour characteristics.
